Leah Lawrence is a journalist at OBR, specializing in medicine and healthcare with a focus on oncology, immunotherapy, palliative care, and hematology. Her work delves into various medical specialties, providing insights and information that resonate with healthcare professionals and patients alike. Leah's articles have been featured in numerous reputable publications, including Oncology Nurse Advisor, Medical Bag, and CURE Media Group.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Leah's articles predominantly focus on healthcare and pharmaceuticals, specifically cancer research and treatment. Her coverage heavily relies on citing data, indicating a preference for evidence-based information.
To effectively reach Leah, consider providing pitches backed by robust scientific or clinical data related to the topics she covers. Additionally, offering access to experts in the field who can offer insights into recent studies or developments in cancer research and treatment may be beneficial.
Given that Leah has no specified geographic focus, relevant information from any location would likely be of interest as long as it contributes to advancing knowledge within the areas of cancer research and treatment.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Leah Lawrence
In recent years, the FDA approved bispecific antibodies for use in patients with multiple myeloma, lymphoma, and other conditions. At least some of these therapies have package labels that require inpatient administration; however, as the number of approvals increases, so does interest in outpatient use.
By: Leah Lawrence
ASCO has released a guideline update addressing advances in the use of immunotherapy and targeted therapy for the treatment of advanced gastroesophageal cancer. 1 The guideline, last updated in 2023 to include first-line therapy recommendations for patients with biomarkers such as PD-L1 and HER2, now reflects new targeted therapy options in the first-line setting, providing the most up-to-date treatment information for clinicians.
By: Leah Lawrence
The addition of relacorilant (Lifyorli) to nab-paclitaxel resulted in improved overall survival compared with nab-paclitaxel alone in patients with platinum-resistant ovarian cancer, according to results from the final analysis of the phase 3 ROSELLA trial presented at the 2026 SGO Annual Meeting on Women’s Cancer.
By: Leah Lawrence
Letrozole monotherapy failed to demonstrate noninferiority to chemotherapy followed by letrozole in patients with stage II–IV low-grade serous ovarian carcinoma, according to results from the NRG-GY019 trial that were presented at the 2026 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
By: Leah Lawrence
Selinexor combined with ruxolitinib improves spleen response in myelofibrosis patients, offering a new treatment avenue.
By: Leah Lawrence
'Most of the time we undertreat,' says expert
The treatment landscape for these patients is evolving
Learn how tafasitamab with lenalidomide and R-CHOP enhances survival in high-risk diffuse large B-cell lymphoma in the phase 3 frontMIND trial.
By: Leah Lawrence
Teclistamab improves response rates and progression-free survival in high-risk smoldering multiple myeloma, per phase 2 trial data.
By: Leah Lawrence
Talquetamab-containing regimens significantly improve progression-free survival in patients with relapsed or refractory multiple myeloma, according to the MonumenTAL-3 trial.
